



Pergamon

Tetrahedron Letters 40 (1999) 7185–7188

TETRAHEDRON
LETTERS

Solid phase synthesis of highly substituted 2,4-dioxopiperidines

Wenyng Chai * and William V. Murray

The R. W. Johnson Pharmaceutical Research Institute, 3210 Merryfield Row, San Diego, California 92121, USA

Received 20 April 1999; accepted 27 July 1999

Abstract

A convenient solid phase synthesis of (*E*)-*N*-substituted-acetyl-*N*-(2-methoxycarbonyl-3-(aryl)-prop-2-enyl)amino acids and the condensation of their esters to highly substituted 2,4-dioxopiperidines are described. © 1999 Elsevier Science Ltd. All rights reserved.


2,4-Dioxopiperidines have been shown to possess biological activity in a number of therapeutic areas. Recently, various 2,4-dioxopiperidines were found to be potent as therapeutic or prophylactic agents for hepatic disease, for bacterial and viral infections and for diseases including AIDS.¹ But the synthesis of a novel highly substituted 2,4-dioxopiperidine **7** which has potential to be further functionalized has never been reported. Herein a general method was developed to synthesize various highly substituted 2,4-dioxopiperidines **7** via solid-phase synthesis of (*E*)-*N*-substituted-acetyl-*N*-(2-methoxycarbonyl-3-(aryl)-prop-2-enyl)amino acids **5**.

The solid phase synthesis was initiated with Fmoc-protected amino acid-Wang resin **1** (Scheme 1). Various commercially available Fmoc-amino acid-Wang resin units provide the first diversity element in **R**¹ of 2,4-dioxopiperidines **7**. After removal of the Fmoc group of **1**, alkylation of the free amines **2** was accomplished by Pd(0) catalyzed reaction with methyl 2-(*Z*)-(bromomethyl)-3-aryl-prop-2-enoates **3**^{2,3} in DMF.


The bromides **3** were synthesized in two steps. The first step is a DABCO catalyzed Baylis–Hillman reaction of methyl acrylate with the appropriate aldehyde.² The second step involves a Corey–Kim bromination using NBS–DMS (Scheme 2).³ The alkylation with the bromide **3** gives the second element of diversity (**R**²) to the 2,4-dioxopiperidines **7**.

The subsequent amidation step generates the third diversity element (**R**³)⁴ of **7** by the use of different amidating reagents (Scheme 1, Table 1): (1) compound **4** reacted with ethyl malonyl chloride, pyridine, and DMAP in CH₂Cl₂ providing *N*-ethoxycarbonylacetyl amides **5**;^{5,6} (2) compound **4** reacted with cyanoacetic acid, and DIC in DMF giving *N*-cyanoacetyl amide **5**;⁷ (3) compound **4** reacted with diketene, and NEt₃ in CH₂Cl₂ generating *N*-methylcarbonylacetyl amide **5**.⁸

* Corresponding author.



Scheme 1.



Scheme 2.

Table 1

The reaction conditions of amide formation for compound 5

5	Amidation	
	Reaction Conditions	R ³
(1)	ethyl malonyl chloride pyridine/DMAP/CH ₂ Cl ₂ /16h	COOC ₂ H ₅
(2)	cynoacetic acid DIC/DMF/50h	CN
(3)	diketene/NEt ₃ /CH ₂ Cl ₂ /50h	COCH ₃


After resin cleavage with $\text{CF}_3\text{COOH}/\text{MeOH}$, and methylation with TMSCHN_2 in MeOH , the methyl esters **6** were obtained. Three diversities (R^1 , R^2 , and R^3) were generated. The isolated yields for pure **6** are 28–31% after five step reaction from **1**.⁹ Finally, Dieckmann condensation of **6** with $t\text{BuOK}$ in THF at -78°C provided different highly substituted 2,4-dioxopiperidines **7** in 60–72% yields (Table 2).^{10–13}

In summary, solid phase synthesis of (*E*)-*N*-substituted-acetyl-*N*-(2-methoxycarbonyl-3-(aryl)-prop-2-enyl)amino acids **5** is accessible from commercially available Fmoc-protected aminoacids on Wang resin. The synthesis requires an alkylation and subsequent amidation step. This approach can be used to generate number compound libraries of **5** with three diversity elements (R^1 , R^2 and R^3). The methyl ester **6** can be further elaborated to various 2,4-dioxopiperidines **7**.

1. Typical experimental procedures

Compound 4a: To the Fmoc-Ala-Wang resin **1a** (Novabiochem, 0.74 mmol/g) (1 g, 0.74 mmol) was added a solution containing 5 mL each of DMF and piperidine at room temperature. The suspension was allowed to mix at room temperature for 2 h. Then the supernatant was removed. The resin was washed with DMF , MeOH , CH_2Cl_2 , and dried in vacuo. To the dried resin were added methyl (bromomethyl)-3-(4-methoxycarbonylphenyl)prop-2-enoate **3**^{2,3} (231 g, 0.74 mmol), $\text{Pd}(\text{PPh}_3)_4$ (8.6 mg, 0.0074 mmol),

Table 2
The yields for Dieckmann condensation

 7	7	R ¹	R ²	R ³	% Yields
	a	CH ₃	COOCH ₃	COOC ₂ H ₅	64
b	CH(CH ₃)CH ₂ CH ₃	COOCH ₃	COOC ₂ H ₅	60	
c	CH(CH ₃)CH ₂ CH ₃	Br	COOC ₂ H ₅	72	
d	CH(CH ₃)CH ₂ CH ₃	Br	CN	60	
e	CH ₂ Ph	COOCH ₃	COCH ₃	65	

Cs₂CO₃ (241 mg, 0.74 mmol) and DMF (10 mL) at room temperature. The suspension was allowed to mix at room temperature for 16 h. After 16 h, the supernatant was removed. The resin was washed with DMF, MeOH, and CH₂Cl₂ and then dried in vacuo.

Compound **5a**: A mixture of the above resin, pyridine (120 μ L, 1.48 mmol), DMAP (0.9 mg, 0.0074 mmol) in CH₂Cl₂ (10 mL) was stirred at 0°C for 20 min. Ethyl 3-chloro-3-oxopropionate (188 μ L, 1.48 mmol) was added. The suspension was stirred for 16 h at 25°C before the supernatant was removed. The resin was washed with MeOH, and CH₂Cl₂ and dried in vacuo.

Compound **6a**: To the above resin, TFA (10 mL) was added. The suspension was stirred for 2 h at 25°C. Then the supernatant was removed, and the resin was washed with MeOH (3 \times 8 mL). The combined supernatants were concentrated and dried in vacuo. The residue was redissolved in MeOH (10 mL), and (trimethylsilyl)diazomethane (2.0 M solution in hexanes) was added dropwise until the yellow color stayed. After concentration, chromatography (EtOAc/hexane) of the crude yellow oil afforded **6a** 100 mg (total yield 30% from **1a** to **6a**): ¹H NMR (CD₃OD, 500 MHz) δ 8.10–8.08 (d, 2H, *J*=8.2 Hz), 7.96 (d, 1H), 7.50–7.48 (d, 2H, *J*=8.2 Hz), 4.60–4.56 (d, 1H, *J*=15.5 Hz), 4.48–4.45 (d, 1H, *J*=15.5 Hz), 4.17–4.12 (m, 2H), 3.93 (s, 3H), 3.87 (s, 3H), 3.80–3.60 (m, 3H), 3.57 (s, 3H), 1.26–1.23 (t, 3H, *J*=6.9 Hz), 1.18–1.16 (d, 3H, *J*=6.9 Hz); ¹³C NMR (CD₃OD, 500 MHz) δ 172.8, 169.3, 169.1, 168.4, 167.9, 143.6, 140.2, 132.0, 131.5, 131.0, 130.6, 62.6, 56.2, 53.0, 52.9, 52.7, 46.0, 42.1, 14.5, 13.9; EIMS *m/z* 472 (M+Na⁺).

Compound **7a**: The above **6a** (83 mg, 0.185 mmol) in THF (10 mL) was cooled down to –78°C. Potassium *tert*-butoxide (1.0 M solution in 2-methyl-2-propanol) (0.5 mL, 0.5 mmol) was added. The mixture was stirred for 3 h at –78°C. The reaction mixture was quenched by saturated NH₄Cl solution (10 mL). The organic layer was removed. The aqueous layer was extracted by EtOAc (2 \times 10 mL). The combined organic layers were washed by saturated NaCl solution (20 mL), dried over Na₂SO₄, and concentrated. Chromatography (CH₂Cl₂/MeOH) of the crude yellow oil afforded **7a** 50 mg (64%): ¹H NMR (CD₃OD, 500 MHz) δ 8.04–8.02 (d, 2H, *J*=7.5 Hz), 7.81 (s, 1H), 7.60–7.58 (d, 2H, *J*=7.5 Hz), 5.10 (1H, overlapped with water peak), 4.17–4.13 (m, 3H), 3.90 (s, 3H), 3.80 (s, 3H), 3.34 (s, 1H), 3.30–3.28 (broad, 1H), 1.29–1.23 (t, 3H, *J*=6.0 Hz), 1.24–1.23 (d, 3H, *J*=6.1 Hz); ¹³C NMR (CD₃OD, 500 MHz) δ 196.5, 175.4, 169.5, 168.2, 167.7, 141.6, 140.9, 132.4, 131.4, 130.9, 130.7, 90.7, 59.4, 53.0, 52.9, 49.3, 37.3, 16.8, 15.2; EIMS *m/z* 418 (M+H⁺), 440 (M+Na⁺).

References

1. (a) Lijima, I.; Homma, K.; Saiga, Y.; Matsuoka, Y.; Matsumoto, M. (Tanabe Seiyaku Co., Ltd., Japan). Eur. Pat. Appl., 76pp. EP 0149534. (b) Ellsworth, E. L.; Lunney, E.; Tait, B. (Parke, Davis & Company, USA). PCT Int. Appl., 133pp. WO 9514012.
2. (a) Rabe, J.; Hoffmann, H. M. R. *Angew. Chem., Int. Ed. Engl.* **1983**, *22*, 796–797. (b) Rafel, S.; Leahy, J. W. *J. Org. Chem.* **1997**, *62*, 1521–1522.
3. (a) Corey, E. J.; Kim, C. U.; Takeda, M. *Tetrahedron Lett.* **1972**, 4339–4342. (b) Hoffmann, H. M. R.; Rabe, J. *Helv. Chim. Acta* **1984**, *67*, 413–415. (c) Buchholz, R.; Hoffmann, H. M. R. *Helv. Chim. Acta* **1991**, *74*, 1213–1220.
4. R^3 demonstrated here are all acidifying groups. Certainly this is not a requirement. For example, R^3 can be an alkyl group, this type of cyclization was reported in Ref. 12b.
5. (a) Barnish, I. T.; Corless, M.; Dunn, P. J.; Ellis, D.; Finn, P. W.; Hardstone, J. D.; James, K. *Tetrahedron Lett.* **1993**, *34*, 1323–1326. (b) Marson, C. M.; Pink, J. H.; Smith, C. *Tetrahedron Lett.* **1995**, *36*, 8107–8110.
6. Lai, J. H.; Pham, H.; Hangauer, D. G. *J. Org. Chem.* **1996**, *61*, 1872–1874.
7. Piskunova, I. P.; Eremeev, A. V.; Mishnev, A. F.; Vosekalna, I. A. *Tetrahedron* **1993**, *49*, 4671–4676.
8. Wulferding, A.; Jankowski, J. H.; Hoffmann, H. M. R. *Chem. Ber.* **1994**, *127*, 1275–1281.
9. NMR and LCMS of crude sample **6** show good efficiency (yields greater than 80%). Compounds **6** are highly functionalized molecules. Low isolation yields are due to the loss of resin washing and transferring (flasks and Buchner funnel were used for the reactions and workup, no special solid phase apparatus) in the five step reaction sequence, purification process and compound stability.
10. Various reaction conditions for the Dieckmann condensation of **6** to **7** were utilized: the room temperature reaction resulted in decomposition. Low reaction temperature (-78°C) and good purity of starting material **6** provided good yields of **7**.
11. No epimerization of R^1 was observed in this Dieckmann condensation. This might be due to very low reaction temperature (-78°C). In the transformation of **6b** to **7b**, **6c** to **7c**, and **6d** to **7d**, the α -CH of the isoleucine group is always shown as a simple doublet, no other doublet was seen for the other diastereomer in the ^1H NMR spectra.
12. (a) Ashton, M. J.; Hills, S. J.; Newton, C. G.; Taylor, J. B.; Tudou, S. C. D. *Heterocycles* **1989**, *28*, 1015–1035. (b) Akiba, K.-y.; Nakatani, M.; Wada, M.; Yamamoto, Y. *J. Org. Chem.* **1985**, *50*, 63–68.
13. Compounds **6** and **7** were characterized by ^1H , ^{13}C NMR, and ESMS. (*E*)/(*Z*) Configurations were determined by NOE.